Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
140.1 USD | +4.81% | +5.34% | +6.32% |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 14.09B |
---|---|---|---|---|---|
Net income 2024 * | 490M | Net income 2025 * | 666M | EV / Sales 2024 * | 5.33 x |
Net cash position 2024 * | 2.3B | Net cash position 2025 * | 3.04B | EV / Sales 2025 * | 4.39 x |
P/E ratio 2024 * |
29.7
x | P/E ratio 2025 * |
22
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +4.81% | ||
1 week | +5.34% | ||
Current month | +1.57% | ||
1 month | -0.95% | ||
3 months | -0.23% | ||
6 months | +29.82% | ||
Current year | +6.32% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 215 M€ | +11.92% | - | |
3.81% | 1 M€ | 0.00% | - | |
1.85% | 8 M€ | -.--% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 140.1 | +4.81% | 1,607,818 |
24-04-22 | 133.7 | +1.26% | 575,067 |
24-04-19 | 132 | -0.41% | 556,303 |
24-04-18 | 132.5 | -0.52% | 586,541 |
24-04-17 | 133.2 | +0.18% | 571,093 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.32% | 14.09B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+1.66% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+21.46% | 10.99B | |
-21.14% | 8.63B |
- Stock Market
- Equities
- NBIX Stock